Literature DB >> 31646568

LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.

F-Y Zhu1, S-R Zhang, L-H Wang, W-D Wu, H Zhao.   

Abstract

OBJECTIVE: Lung cancer is a malignant tumor with extremely high morbidity and mortality. Recent studies have identified the vital role of LINC00511 (lncRNAs) in the development and progression of non-small cell lung cancer (NSCLC). In this research, we aim to explore the biological function of LINC00511 in the development and metastasis of NSCLC. PATIENTS AND METHODS: LINC00511 expression in 57 paired NSCLC patients' tissues and matched normal tissues were detected by Real-time quantitative polymerase chain reaction (RT-qPCR). Cell proliferation assay, colony formation assay and transwell assay were conducted to observe the biological behavior changes of NSCLC cells through the influence of LINC00511. In addition, dual-luciferase reporter gene assay, RNA immunoprecipitation assay (RIP) and, chromatin immunoprecipitation (ChIP) were performed to discover the potential targets of LINC00511 in NSCLC cells.
RESULTS: LINC00511 was highly expressed in NSCLC tissues and cell lines compared with controls. LINC00511 expression was positively correlated with tumor size, tumor stage, lymph node metastasis and distant metastasis, but negatively correlated with overall survival (OS) of NSCLC patients. Receiver Operating Characteristic (ROC) curves suggested that LINC00511 could be an effective indicator to distinguish NSCLC patients from normal people. Cell counting kit-8 (CCK-8), flow cytometry and transwell assay showed that knockdown of LINC00511 in A549 cells decreased viability, accelerated apoptosis and inhibited invasive and migratory abilities. Overexpression of LINC00511 in PC9 cells obtained the opposite biological effects. Chromatin fractionation predicted that LINC00511 was mainly distributed in the nucleus. RIP and ChIP assay showed that LINC00551 directly bound to lysine-specific demethylase 1 (LSD1) and enhancer of zeste homolog 2 (EZH2). It inhibited expressions of LATS2 and KLF2 by binding to their promoter regions.
CONCLUSIONS: LINC00511 is upregulated in NSCLC tissues and cell lines. It is closely related to tumor size, tumor stage, lymph node metastasis and, distant metastasis of NSCLC patients. Knockdown of LINC00511 attenuates proliferative, migratory and invasive capacities, but induces apoptosis of NSCLC cells. LATS2 and KLF2 are target genes of LINC00511, which are regulated by LINC00511 through binding to EZH2 and LSD1, thus influencing the progression of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31646568     DOI: 10.26355/eurrev_201910_19149

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  19 in total

Review 1.  Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Authors:  Cui Wu; Wu Song; Zhongnan Wang; Bingmei Wang
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

2.  LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5.

Authors:  Zhongcheng Zhu; Yufeng Shi; Xiaoyi Gong; Jing Li; Mingyun Zhang
Journal:  Mol Biotechnol       Date:  2021-09-30       Impact factor: 2.695

3.  RETRACTED ARTICLE: The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2.

Authors:  Dan Sun; Ying Wang; Huan Wang; Yan Xin
Journal:  Cancer Cell Int       Date:  2020-05-29       Impact factor: 6.429

4.  LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.

Authors:  Yudong Wang; Xingke Mei; Weikang Song; Chen Wang; Xueshan Qiu
Journal:  BMC Pulm Med       Date:  2022-07-16       Impact factor: 3.320

5.  lncRNA TM4SF1-AS1 Activates the PI3K/AKT Signaling Pathway and Promotes the Migration and Invasion of Lung Cancer Cells.

Authors:  Fachen Zhou; Jin Wang; Xinming Chi; Xin Zhou; Zhou Wang
Journal:  Cancer Manag Res       Date:  2020-07-07       Impact factor: 3.989

6.  Long Non-Coding RNA LINC00511 Accelerates Proliferation and Invasion in Cervical Cancer Through Targeting miR-324-5p/DRAM1 Axis.

Authors:  Xin Zhang; Yuyan Wang; Anqi Zhao; Fanshuang Kong; Lipeng Jiang; Jinfeng Wang
Journal:  Onco Targets Ther       Date:  2020-10-12       Impact factor: 4.147

Review 7.  The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review.

Authors:  Jianlong Ding; Junyan Cao; Zhaocong Chen; Zhiming He
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

8.  Long Intergenic Non-protein Coding RNA 511 in Cancers.

Authors:  Xiao-Fei Wang; Bo Liang; Cheng Chen; Da-Xiong Zeng; Yu-Xiu Zhao; Nan Su; Wei-Wei Ning; Wen Yang; Jian-An Huang; Ning Gu; Ye-Han Zhu
Journal:  Front Genet       Date:  2020-07-07       Impact factor: 4.599

9.  LINC00511 as a prognostic biomarker for human cancers: a systematic review and meta-analysis.

Authors:  Yannick Luther Agbana; Manzama-Esso Abi; Yueli Ni; Guohang Xiong; Jing Chen; Fang Yun; Zihan Yi; Qiao Zhang; Zhe Yang; Yingmin Kuang; Yuechun Zhu
Journal:  BMC Cancer       Date:  2020-07-22       Impact factor: 4.430

10.  The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2.

Authors:  Dan Sun; Ying Wang; Huan Wang; Yan Xin
Journal:  Cancer Cell Int       Date:  2020-05-29       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.